Tricyclodecane dimethanol composition, ultraviolet-curable composition, polymer composition, and method for producing tricyclodecane dimethanol composition

By controlling the ratio of isomers in the TCDDM composition and optimizing the distillation purification process, the problem of reduced fluidity during the storage of the TCDDM composition was solved, and the storage stability and operability were improved.

CN120712247BActive Publication Date: 2026-07-10MITSUBISHI CHEM CORP
View PDF 10 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
MITSUBISHI CHEM CORP
Filing Date
2024-09-11
Publication Date
2026-07-10

AI Technical Summary

Technical Problem

In the prior art, the TCDDM composition obtained after hydrogen reduction reaction has reduced fluidity during storage, resulting in poor operability and difficulty in effectively improving its storage stability.

Method used

By controlling the ratio of different isomers in the TCDDM composition, especially the molar ratio of chiral compounds A, B, C, and D, ensuring that Xa/Xt ≤ 0.430, Xb/Xt ≥ 0.016, Xc/Xt ≥ 0.300, and Xd/Xt ≥ 0.240, and detecting them under specific gas chromatographic conditions, the distillation purification process is optimized to control the content of isomers.

Benefits of technology

A balance between long-term storage stability and flowability of the TCDDM composition was achieved, avoiding a decrease in flowability and ensuring ease of operation and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120712247B_ABST
    Figure CN120712247B_ABST
Patent Text Reader

Abstract

A tricyclodecane dimethanol composition containing a chiral compound A in which one of enantiomeric forms is represented by the following formula (I), a chiral compound B in which one of enantiomeric forms is represented by the following formula (II), a chiral compound C in which one of enantiomeric forms is represented by the following formula (III), and a chiral compound D in which one of enantiomeric forms is represented by the following formula (IV), the number of moles Xa of the chiral compound A, the number of moles Xb of the chiral compound B, and the total number of moles Xt of the number of moles of the chiral compound A, the chiral compound B, the chiral compound C, and the chiral compound D determined by nuclear magnetic resonance spectroscopy satisfy Xa / Xt ≤ 0.430 and Xb / Xt ≥ 0.016.
Need to check novelty before this filing date? Find Prior Art